GB0423974D0 - Proteins - Google Patents

Proteins

Info

Publication number
GB0423974D0
GB0423974D0 GBGB0423974.5A GB0423974A GB0423974D0 GB 0423974 D0 GB0423974 D0 GB 0423974D0 GB 0423974 A GB0423974 A GB 0423974A GB 0423974 D0 GB0423974 D0 GB 0423974D0
Authority
GB
United Kingdom
Prior art keywords
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0423974.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Priority to GBGB0423974.5A priority Critical patent/GB0423974D0/en
Publication of GB0423974D0 publication Critical patent/GB0423974D0/en
Priority to CN2005800441605A priority patent/CN101115767B/zh
Priority to AU2005298445A priority patent/AU2005298445B2/en
Priority to EP05798912A priority patent/EP1812462A2/en
Priority to PCT/GB2005/004191 priority patent/WO2006046072A2/en
Priority to EA200700951A priority patent/EA013251B1/ru
Priority to CA002584732A priority patent/CA2584732A1/en
Priority to BRPI0517362-0A priority patent/BRPI0517362A/pt
Priority to KR1020077010847A priority patent/KR20070085342A/ko
Priority to MX2007005054A priority patent/MX2007005054A/es
Priority to US11/718,183 priority patent/US8222371B2/en
Priority to UAA200705860A priority patent/UA93661C2/ru
Priority to JP2007538515A priority patent/JP2008517616A/ja
Priority to IL182749A priority patent/IL182749A/en
Priority to NO20072076A priority patent/NO20072076L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
GBGB0423974.5A 2004-10-28 2004-10-28 Proteins Ceased GB0423974D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0423974.5A GB0423974D0 (en) 2004-10-28 2004-10-28 Proteins
JP2007538515A JP2008517616A (ja) 2004-10-28 2005-10-28 ｖＷＦＡ及び／又はＡＮＴ＿ＩＧドメイン含有タンパク質
CA002584732A CA2584732A1 (en) 2004-10-28 2005-10-28 Vwfa and/or ant_ig domain containing proteins
KR1020077010847A KR20070085342A (ko) 2004-10-28 2005-10-28 ｖＷＦＡ 및/또는 ＡＮＴ_ＩＧ 도메인 보유 단백질
EP05798912A EP1812462A2 (en) 2004-10-28 2005-10-28 Vwfa and/or ant_ig domain containing proteins
PCT/GB2005/004191 WO2006046072A2 (en) 2004-10-28 2005-10-28 VWFA AND/OR ANT_IG DOMAIN CONTAINING PROTEINS
EA200700951A EA013251B1 (ru) 2004-10-28 2005-10-28 БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
CN2005800441605A CN101115767B (zh) 2004-10-28 2005-10-28 包含vWFA和/或ANT＿IG结构域的蛋白质
BRPI0517362-0A BRPI0517362A (pt) 2004-10-28 2005-10-28 polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, anticorpo, métodos in vitro para diagnosticar uma doença em um paciente, composição farmacêutica, composição de vacina, uso de um polipeptìdeo, proteina de fusão, e, método para produção de proteìna
AU2005298445A AU2005298445B2 (en) 2004-10-28 2005-10-28 vWFA and/or ANT_IG domain containing proteins
MX2007005054A MX2007005054A (es) 2004-10-28 2005-10-28 Proteinas que contienen el factor a de von willebrand y dominios extracelulares del receptor de antrax.
US11/718,183 US8222371B2 (en) 2004-10-28 2005-10-28 vWFA and/or ANT—IG domain containing proteins
UAA200705860A UA93661C2 (ru) 2004-10-28 2005-10-28 БЕЛКИ, КОТОРЫЕ СОДЕРЖАТ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
NO20072076A NO20072076L (no) 2004-10-28 2007-04-23 VWFA og/eller ANT_IG holdige proteiner
IL182749A IL182749A (en) 2004-10-28 2007-04-23 Vwfa and/or ant_ig domain containing proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0423974.5A GB0423974D0 (en) 2004-10-28 2004-10-28 Proteins

Publications (1)

Publication Number Publication Date
GB0423974D0 true GB0423974D0 (en) 2004-12-01

Family

ID=33515721

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0423974.5A Ceased GB0423974D0 (en) 2004-10-28 2004-10-28 Proteins

Country Status (15)

Country Link
US (1) US8222371B2 (https=)
EP (1) EP1812462A2 (https=)
JP (1) JP2008517616A (https=)
KR (1) KR20070085342A (https=)
CN (1) CN101115767B (https=)
AU (1) AU2005298445B2 (https=)
BR (1) BRPI0517362A (https=)
CA (1) CA2584732A1 (https=)
EA (1) EA013251B1 (https=)
GB (1) GB0423974D0 (https=)
IL (1) IL182749A (https=)
MX (1) MX2007005054A (https=)
NO (1) NO20072076L (https=)
UA (1) UA93661C2 (https=)
WO (1) WO2006046072A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257445B2 (en) 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
CA2617877A1 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
KR101808751B1 (ko) * 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
RU2013131870A (ru) * 2013-07-11 2015-01-20 Павлов Владимир Игоревич Способ обнаружения наличия, тяжести, риска и предрасположенности к рецидивам, а также лечения и реакции на лечение воспаления мочевыводящих путей и наборы для его описания
BR102019017792A2 (pt) * 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
AU2022287910A1 (en) * 2021-06-07 2023-12-14 Michael L. MARTINO Rapid recognition based diagnosis and treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2416732C (en) 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
EP1293569A3 (en) 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
WO2003033515A1 (en) 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20030144193A1 (en) * 2001-12-20 2003-07-31 Rottman James B. TANGO 197 and TANGO 216 compositions and methods
AU2003281867A1 (en) * 2002-03-28 2004-02-23 University Of Florida Antisense nucleic acids
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules

Also Published As

Publication number Publication date
KR20070085342A (ko) 2007-08-27
WO2006046072A3 (en) 2007-01-25
UA93661C2 (ru) 2011-03-10
WO2006046072A2 (en) 2006-05-04
IL182749A0 (en) 2007-07-24
AU2005298445B2 (en) 2011-08-25
AU2005298445A1 (en) 2006-05-04
MX2007005054A (es) 2007-06-19
IL182749A (en) 2012-09-24
EP1812462A2 (en) 2007-08-01
EA013251B1 (ru) 2010-04-30
BRPI0517362A (pt) 2008-10-07
CA2584732A1 (en) 2006-05-04
US8222371B2 (en) 2012-07-17
CN101115767B (zh) 2011-06-22
JP2008517616A (ja) 2008-05-29
US20090104197A1 (en) 2009-04-23
NO20072076L (no) 2007-07-25
CN101115767A (zh) 2008-01-30
EA200700951A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
EP1766073A4 (en) IMPROVING PROTEIN EXPRESSION
GB0423974D0 (en) Proteins
GB0417887D0 (en) Protein
GB0423002D0 (en) Proteins
GB0401882D0 (en) Protein
GB0416035D0 (en) Protein
GB0404929D0 (en) Protein
GB0418666D0 (en) Proteins
GB0415161D0 (en) Proteins
GB0412570D0 (en) Proteins
GB0411678D0 (en) Proteins
GB0405885D0 (en) Proteins
GB0418248D0 (en) Proteins
GB0405643D0 (en) Proteins
GB0511861D0 (en) Proteins
GB0421200D0 (en) Protein
GB0413407D0 (en) Protein
GB0402088D0 (en) Protein
GB0402662D0 (en) Protein
GB0427992D0 (en) Trem-like Protein
GB0426962D0 (en) Protein
GB0425733D0 (en) Protein
GB0422440D0 (en) Protein
GB0422058D0 (en) Protein
GB0400784D0 (en) Protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)